520 related articles for article (PubMed ID: 10914704)
21. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
Kozin SV; Boucher Y; Hicklin DJ; Bohlen P; Jain RK; Suit HD
Cancer Res; 2001 Jan; 61(1):39-44. PubMed ID: 11196192
[TBL] [Abstract][Full Text] [Related]
22. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
23. [Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor KDR].
Chen XL; Liu LC; Xu ZG; Li Z; Li RW; Gao RJ; Wang S; Zhang M; Guo H
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):578-82. PubMed ID: 19102933
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
[TBL] [Abstract][Full Text] [Related]
25. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.
Shaheen RM; Tseng WW; Vellagas R; Liu W; Ahmad SA; Jung YD; Reinmuth N; Drazan KE; Bucana CD; Hicklin DJ; Ellis LM
Int J Oncol; 2001 Feb; 18(2):221-6. PubMed ID: 11172585
[TBL] [Abstract][Full Text] [Related]
26. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
Clin Cancer Res; 2003 Feb; 9(2):886-99. PubMed ID: 12576464
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
Suzuki K; Morita T; Tokue A
Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109
[TBL] [Abstract][Full Text] [Related]
29. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP
Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor.
Inoue K; Perrotte P; Wood CG; Slaton JW; Sweeney P; Dinney CP
Clin Cancer Res; 2000 Nov; 6(11):4422-31. PubMed ID: 11106263
[TBL] [Abstract][Full Text] [Related]
31. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
[TBL] [Abstract][Full Text] [Related]
32. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder.
Chikazawa M; Inoue K; Fukata S; Karashima T; Shuin T
Pathobiology; 2008; 75(6):335-45. PubMed ID: 19096229
[TBL] [Abstract][Full Text] [Related]
33. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
34. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
[TBL] [Abstract][Full Text] [Related]
35. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
Inoue K; Kamada M; Slaton JW; Fukata S; Yoshikawa C; Tamboli P; Dinney CP; Shuin T
Clin Cancer Res; 2002 Jun; 8(6):1863-70. PubMed ID: 12060629
[TBL] [Abstract][Full Text] [Related]
37. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
39. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
Dagnaes-Hansen F; Rasmussen LM; Tilton R; Denner L; Flyvbjerg A
Anticancer Res; 2003; 23(2B):1625-30. PubMed ID: 12820432
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
